医学
来曲唑
阿那曲唑
戈塞雷林
乳腺癌
芳香化酶抑制剂
肿瘤科
癌症
中期分析
内科学
临床终点
三苯氧胺
妇科
随机对照试验
作者
Dennis J. Slamon,Oleg Lipatov,Zbigniew Nowecki,Nicholas P. McAndrew,Bożena Kukiełka-Budny,Daniil Stroyakovskiy,Denise A. Yardley,Chiun‐Sheng Huang,Peter A. Fasching,John Crown,Aditya Bardia,Stephen Chia,Seock‐Ah Im,Manuel Ruíz-Borrego,Sherene Loi,Binghe Xu,Sara A. Hurvitz,Carlos H. Barrios,Michael Untch,Rebecca Moroose
标识
DOI：10.1056/nejmoa2305488
摘要
Ribociclib plus an NSAI significantly improved invasive disease-free survival among patients with HR-positive, HER2-negative stage II or III early breast cancer. (Funded by Novartis; NATALEE ClinicalTrials.gov number, NCT03701334.).
科研通智能强力驱动
Strongly Powered by AbleSci AI
PDF的下载单位、IP信息已删除
(2025-6-4)
Kao
无极微光
OK
Criminology34
GingerF
cdercder
老胡
Nole
liuxinyu
sagitar
七月不远
科研甜菜
Copyright
cnspower
zz
rebron
王雪
wueeee
3G就是牛
aaaa
皖公网安备34019202002308
